Skip to main
  1. Stocks
  2. Rigel Pharmaceuticals
  3. Forecast
RIGL

Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target

Rigel Pharmaceuticals (RIGL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Rigel Pharmaceuticals is viewed positively because it is transitioning into a multi-product commercial-stage company with narrower 2024 revenue guidance of $290M-$295M, while also ending the quarter with about $99M in cash and equivalents and guiding to positive net income for the full year. The first reported quarter of VEPPANU showed $6.6M in net product sales from mid-August to quarter-end, shipment to 100+ patients/clinics, and strong refill rates, which supports the thesis that real-world physician experience could drive substantial uptake. In addition, Gavreto’s clinical activity across RET fusion-positive tumors, including a 53% overall response rate in pooled solid tumors and 88% in previously treated pancreatic cancer, alongside encouraging R289 signals, reinforces the company’s diversified growth potential.

Bears say

Rigel Pharmaceuticals is facing a negative fundamental setup because its lead asset fostamatinib recently missed the primary endpoint in the pivotal warm AIHA trial, weakening confidence in clinical success and raising the risk of regulatory rejection or the need for additional studies. The company also remains highly exposed to stringent FDA and international oversight, while commercialization of its approved products is vulnerable to competitive pressure in ITP and to physicians’ reluctance to switch from established therapies. With a narrow pipeline concentrated in risky development-stage programs, limited execution would further diminish the drug’s market potential and the broader investment case.

Rigel Pharmaceuticals (RIGL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rigel Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Rigel Pharmaceuticals (RIGL) Analyst Forecast & Price Prediction

Get the latest Rigel Pharmaceuticals (RIGL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Rigel Pharmaceuticals (RIGL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rigel Pharmaceuticals (RIGL) Forecast

Analysts have given Rigel Pharmaceuticals (RIGL) a Buy based on their latest research and market trends.

According to 4 analysts, Rigel Pharmaceuticals (RIGL) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $66.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $66.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rigel Pharmaceuticals (RIGL)


Rigel Pharmaceuticals (RIGL) Analyst Forecast & Price Prediction

Get the latest Rigel Pharmaceuticals (RIGL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Rigel Pharmaceuticals (RIGL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RIGL stock data and trends